Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

Gabriel N. Hortobagyi, MD
Published: Monday, Oct 17, 2016



Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Patients were randomized to receive letrozole at a dose of 2.5 mg/day or ribociclib at 600 mg/day for 3 weeks on, 1 week off or placebo. Treatment was continued until disease progression, and the primary endpoint was progression-free survival, Hortobagyi says.

At a follow-up, there was such a significant difference between the two arms, it was decided that the trial had reached its primary endpoint. Results showed that there was a 44% reduction in the risk of progression, with a significant P value as well, he adds.
 


Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Patients were randomized to receive letrozole at a dose of 2.5 mg/day or ribociclib at 600 mg/day for 3 weeks on, 1 week off or placebo. Treatment was continued until disease progression, and the primary endpoint was progression-free survival, Hortobagyi says.

At a follow-up, there was such a significant difference between the two arms, it was decided that the trial had reached its primary endpoint. Results showed that there was a 44% reduction in the risk of progression, with a significant P value as well, he adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x